<DOC>
	<DOCNO>NCT02097706</DOCNO>
	<brief_summary>Borderline Personality Disorder ( BPD ) one prevalent psychiatric disorder high morbidity mortality . It affect live million worldwide often highly incapacitate , lead significant psychosocial dysfunction . Moreover , nearly patient experience suicidal ideation 10 % actually commit suicide , rate almost 50 time higher general population . Mostly young woman great risk disorder three time likely diagnose BPD men . BPD aetiology complex could explain biological environmental factor . Among environmental factor , sexual physical abuse , parental divorce , loss illness identified common one . These factor induce dysfunctional behaviour , might cause emotional dysregulation , high impulsivity frequent self- injurious behaviour . However , pharmacologic intervention know specifically effective treat BPD . Therapeutic option devastate disorder still far adequate treat acute illness episode , relapse , recurrence restore premorbid functioning . In addition , patient unable tolerate exist therapy BPD , lead either frequent change medication non-adherence . Therefore urgent need development rapidly effective treatment BPD . A grow body evidence suggest glutamatergic neurotransmission , particular N-methyl-D-aspartate ( NMDA ) subtype may play role pathophysiology multiple psychiatric disorder . This lead various clinical trial glutamate modulate drug . The trial drug uncompetitive NMDA receptor antagonist approve Alzheimer 's disease increasingly studied variety non-dementia psychiatric disorder . Results study prove trial drug safe well tolerate potential use treatment psychiatric disorder . To date , publish data use trial drug treatment BPD . Therefore , investigator intend study efficacy novel drug addition ongoing therapy atypical antipsychotic patient Borderline Personality Disorder . This study recruit 30 BPD patient . The patient randomly allocate receive either study medication ( 20mg/ day ) placebo via oral administration eight week . To observe efficacy trial treatment , participant assess various time interval different borderline cognitive symptom .</brief_summary>
	<brief_title>A Novel Drug Borderline Personality Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<criteria>Inclusion criterion Participants eligible proceed study meet follow criterion ( determine screen session ) : 1 . Men woman age 1865 year age 2 . A diagnosis BPD accord Diagnostic Interview Borderline patient 3 . Proficient read write English Exclusion criterion Potential participant meet criterion follow exclude participate study : 1 . Clinical evidence CNS pathology , neurological disorder , head injury , epileptic seizure convulsion . 2 . Currently pregnant breastfeed 3 . A current DSMIVTR diagnosis substance abuse dependence disorder , another Axis I disorder include past current diagnosis schizophrenia , delusional ( paranoid ) disorder , schizoaffective disorder , bipolar I ( mixed , manic , depressed euthymic ) psychotic depression . Individuals bipolar II include 4 . Clinically significant active evidence liver kidney disease , hematological , respiratory , endocrine cardiovascular disease . 5 . Use prescription drug may cause relevant drug interaction study drug accord summary product characteristic : NMDAR antagonist ( amantadine , ketamine , dextromethorphan ) , LDopa , dopamine agonist cholinergic agonist . 6 . Commencing new psychotherapy/ new medication trial period . 7 . History mental retardation document IQ 75</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Boderline Personality Disorder</keyword>
	<keyword>Mental Illness</keyword>
	<keyword>Cognition</keyword>
</DOC>